Ipsen hands back Parkinson's drug rights to Santhera

French drugmaker Ipsen ($IPN) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it has regained worldwide rights to the experimental drug from Ipsen and is now looking for a new partner for the program, which is set to enter late-stage studies for treating dyskinesia in Parkinson's patients, Reuters reported. In return for handing back rights to the drug to Santhera for markets outside North America and Japan, Ipsen is expected to get a cut of potential milestones and royalties related to fipamezole. Article